Entasis Hires Isaacs From Merck Vaccine Research
Robin David Isaacs is joining Entasis Therapeutics as its chief medical officer. The Waltham, MA-based company is a spinout of AstraZeneca and is focused on creating novel antibiotics with a pathogen-targeted approach. The company’s lead candidate is ETX0914, a treatment of uncomplicated gonorrhea in Phase 2. Isaacs comes from Merck, where he worked for 18 years and was most recently vice president and therapeutic area head for vaccine clinical research.